



SSO 2023

INTERNATIONAL CONFERENCE
ON SURGICAL CANCER CARE™

MARCH

22-25

BOSTON, MA

#SSO2023

SSO2023.ORG

PROGRAM GUIDE

GLOBAL
PERSPECTIVES

INNOVATIVE
CANCER RESEARCH

One
DESTINATION.
A World of
DIVERSITY.

DISEASE-SITE
DATA

COLLABORATE
WITH EXPERTS

WIFI PASSWORD
NETWORK: SSO2023
PASSWORD: surgicaloncology

SSO
SOCIETY OF
SURGICAL
ONCOLOGY
LEADING. TOGETHER.

JOIN US ON FRIDAY



FIRST ANNUAL
**ROCKIN' for
RESEARCH**

FRIDAY, MARCH 24, 2023 | 7 - 9:30 PM

Sheraton Ballroom

Have some fun while supporting the future of surgical oncology research at the first annual *Rockin' for Research*, benefiting the SSO Research and Education Fund. This event features musical entertainment of dueling pianos, drinks and hors d'oeuvres.

This is a ticketed event. You may purchase individual or table tickets by visiting the registration desk or by scanning the QR code.



SSO⁷
RESEARCH
AND
EDUCATION
FUND

The **SSO Research and Education Fund** provides research grants for the SSO Young Investigator and Clinical Investigator Awards. Since the inception of these awards, 44 SSO members have received more than \$4 million in funding for research in numerous disease sites including breast, melanoma, sarcoma and pancreatic cancer. Your support of the SSO surgeon scientist will help to ensure the growth and influence of surgeon scientists.

Mobile Access for SSO 2023

DOWNLOAD THE NEW CONFERENCE APP

by scanning the QR code below or by visiting your app store and searching for “SSO Events.”

The SSO 2023 conference app is your resource for all program schedule details, faculty bios, ePosters, maps, audience response polling and SSO HUB Silent Theater audio connections.

ENHANCE YOUR MEETING EXPERIENCE

Login to the SSO Events App using your SSO credentials to experience the benefits.



GENERAL PROGRAM SCHEDULE

All sessions take place at the Hynes Convention Center unless noted otherwise.

Schedule subject to change. Check mobile app for updates.

WEDNESDAY, MARCH 22

- 12 – 5 PM** **Fellows Institute II** • Room 302
- 1 – 2:30 PM** **Research Pre-Meeting: SSO Grant Writing Workshop and Mock Study Section** • Room 304
- 5:30 – 6:30 PM** **Welcome Reception** • Sheraton Hotel

THURSDAY, MARCH 23

- 6:30 – 7:30 AM** **New Member Breakfast** (*Invitation Only*)
Room 200
- 6:45 – 7:45 AM** **Breakfast Industry Forum (Melanoma)**
Sponsored by Bristol Myers Squibb • Room 306
- 6:45 – 7:45 AM** **Breakfast Industry Forum (Breast)**
Sponsored by AstraZeneca • Room 302
- 8 – 8:15 AM** **Welcome** • Veterans Memorial Auditorium
- 8:15 – 8:45 AM** **James Ewing Lecture: Developing Sustainable Surgical Specialty Programs in East Africa** • Veterans Memorial Auditorium
- 9 – 10 AM** **De-escalation of Surgery for Melanoma** • Ballroom C
- 9 – 10 AM** **Global Good Morning**
(*Invitation Only*) • Room 200
- 9 – 10 AM** **Updates in the Role of Multimodality Therapy for Colorectal Liver Metastases** • Ballroom B

NOTE: International Lounge: Room 204 • Trainee Lounge: Room 210
Check mobile app for hours and special programming.

- 9 – 10 AM** **Value-Based Cancer Care: Where Are We Now?** • *Ballroom A*
- 10:15 – 11:15 AM** **Breast Great Debate: The Surgeon's Role in Locoregional Management of Stage IV Breast Cancer** • *Veterans Memorial Auditorium*
- 10:15 – 11:45 AM** **Colorectal Parallel Session** • *Ballroom C*
- 10:15 – 11:45 AM** **HPB Parallel Session 1** • *Ballroom B*
- 10:15 – 12 PM** **Endocrine/Head & Neck and Sarcoma Parallel Session** • *Ballroom A*
- 11 – 11:45 AM** **Meet the Experts: Current Controversies in the Management of Gastric Cancer***
Room 304
- 11:30 AM – 1:30 PM** **Lunch** • *SSO HUB*
- 12 – 1 PM** **Surgeons Leading Outside the OR: Health System Leadership Opportunities Outside Traditional Academic Practice*** • *Room 302*
- 12:15 – 1:15 PM** **Between Patient and Policy Maker—What We Can Do to Build Global Capacity for Cancer Surgery** • *Ballroom A*
- 12:15 – 1:15 PM** **The Role of Adrenal Metastasectomy in the New Era of Immune Checkpoint Blockade and/or Targeted Therapy** • *Ballroom C*
- 1:30 – 2 PM** **American Cancer Society/SSO Diversity, Equity and Inclusion Lecture: Oncologic Anthropology: Unique Opportunities for Surgeons to Address Global Breast Cancer Disparities**
Veterans Memorial Auditorium
- 2 – 3:30 PM** **Refreshment Break** • *SSO HUB*
- 2:15 – 3:15 PM** **The Use of Circulating Tumor DNA in the Management of Cutaneous Thoracic and Breast Malignancies** • *Ballroom A*
- 2:15 – 3:15 PM** **Management of Extensive PMP** • *Ballroom C*

- 2:15 – 3:15 PM** **Upper GI Great Debate: Chemoradiation Should Be Added to Chemotherapy as Neoadjuvant Treatment Strategy for Resectable Gastric Adenocarcinoma** • *Veterans Memorial Auditorium*
- 3:30 – 4 PM** **Clinical Investigator Award Research Presentation** • *Ballroom C*
- 3:30 – 4 PM** **De-Escalation of Breast Surgery** • *Ballroom B*
- 3:30 – 4 PM** **The Role of Minimal Residual Disease Detection in the Management of GI Cancers** • *Ballroom A*
- 4:30 – 5:30 PM** **Happy Hour** • *SSO HUB*
- 5:30 – 7 PM** **Surgical Oncology Bowl** • *Veterans Memorial Auditorium*
- 7 - 8:30 PM** **Independent Satellite Symposium: Harnessing the Power of Immunotherapy in Resectable Melanoma** • *Room 302*
- 7 - 8:30 PM** **Independent Satellite Symposium: Navigating Complex Decisions at the Intersection of Local and Systemic Management of Early Breast Cancer** • *Room 304*

FRIDAY, MARCH 24

- 6:45 – 7:45 AM** **Breakfast Industry Forum: Adjuvant Treatment Options for Certain Stages of Melanoma** *Sponsored by Merck* • *Room 302*
- 6:45 – 7:45 AM** **Breakfast Industry Forum: The Current State of Desmoid Tumor Management** *Sponsored by SpringWorks Therapeutics* • *Room 306*
- 8 – 8:30 AM** **John Wayne Clinical Research Lecture: Opportunities and Challenges of Clinical Trials in Addressing Cancer Health Disparities** • *Veterans Memorial Auditorium*

- 8:30 – 9 AM** Charles A. Balch Distinguished Service Award and the Clinical Investigator and Young Investigator Awards • *Veterans Memorial Auditorium*
- 9 – 9:30 AM** SSO Presidential Address: Planning for the Future of Surgical Oncology • *Veterans Memorial Auditorium*
- 9:30 – 10:30 AM** SSO Women in Cancer Surgery Breakfast (RSVP Required) • *Room 312*
- 10 – 11 AM** PSM Great Debate: HIPEC for Colorectal PM: Should it be Offered? • *Ballroom B*
- 10 – 11:30 AM** Upper GI Parallel Session • *Ballroom A*
- 10 – 11 AM** Global Partner Poster Presentations • *Ballroom C*
- 10 – 11:45 AM** Melanoma Parallel Session • *Veterans Memorial Auditorium*
- 10:30 – 11:15 AM** Meet the Experts: Controversies in Breast Cancer Surgery* • *Room 302*
- 11:15 AM – 12:15 PM** Careers in DEI/Disparities Research for Surgical Oncologists • *Ballroom C*
- 11:45 AM – 1:30 PM** Lunch • *SSO HUB*
- 12 – 1 PM** Multidisciplinary Management of Cancer Globally • *Room 302*
- 1 – 2:30 PM** Plenary Session 1 • *Veterans Memorial Auditorium*
- 2:45 – 4:15 PM** Plenary Session 2 • *Veterans Memorial Auditorium*
- 3:30 – 4:30 PM** Refreshment Break • *SSO HUB*
- 4:30 – 5:30 PM** Melanoma Great Debate: Limb Infusion: A Thing of the Past? • *Ballroom C*
- 4:30 – 5:30 PM** Neoadjuvant Chemotherapy for Soft Tissue Sarcoma: A Patient-Centric Approach • *Ballroom A*

SSO 2023 will offer participants a maximum of 17.5 AMA PRA Category 1 Credits™ and 5 self-assessment credits which meet the requirement of the self-assessment component of the American Board of Surgery (ABS) Continuous Certification Program.

- 4:30 – 5:30 PM** **Non-Operative Management of Rectal Cancer** • *Ballroom B*
- 4:30 – 6:30 PM** **Breast Parallel Session 1** • *Veterans Memorial Auditorium*
- 5:45 – 6:45 PM** **Ice Cream Social** • *SSO HUB*
- 7:00 – 9:30 PM** **First Annual *Rockin' for Research* Benefiting the SSO Research and Education Fund** • *Sheraton Ballroom*



SATURDAY, MARCH 25

- 7:30 – 8 AM** **Morning Refreshments** • *Ballroom Foyer*
- 7:45 – 8:30 AM** **Meet the Expert: HPB Malignancies*** • *Room 302*
- 8 – 9:30 AM** **Breast Parallel Session 2** • *Veterans Memorial Auditorium*
- 8 – 9:30 AM** **PSM Parallel Session** • *Ballroom B*
- 8:30 – 9:30 AM** **HPB Great Debate: Neoadjuvant Therapy Should Be Routinely Given for High-Risk Intrahepatic Cholangiocarcinoma** • *Ballroom A*
- 9:30 – 9:45 AM** **Refreshment Break** • *Ballroom Foyer*
- 9:45 – 11:15 AM** **Top-Rated Video Abstracts** • *Veterans Memorial Auditorium*
- 9:45 – 11:15 AM** **HPB Parallel Session 2** • *Ballroom A*
- 9:45 – 11:15 AM** **Disparities and Quality Improvement Parallel Session** • *Ballroom B*



All SSO HUB Sessions are Non-CME Sessions

PLEASE REMEMBER TO BRING YOUR EARBUDS TO THE HUB!

The SSO HUB will utilize Silent Theater technology, which requires the use of your cell phone and ear buds.



SSO HUB | THURSDAY, MARCH 23

- 9 – 9:30 AM** Management of Advanced Thyroid Cancer in the Era of Targeted Therapy Endocrine • *HUB Theater*
- 9 – 9:30 AM** Breast Poster Presentations 1 • *Breast/Endocrine Zone*
- 9 – 9:30 AM** Colorectal Poster Presentations 1 • *Pan Tumor Zone*
- 9 – 9:30 AM** The Next Generation of Vaccination Approaches to the Treatment of Cancer: mRNA and Designer Cancer Vaccines • *Immuno-Oncology Zone*
- 9:15 – 10 AM** Disparities Poster Presentations • *Rare/Metastatic Cancers Zone*
- 9:30 – 10 AM** Upper GI Poster Presentations 1 • *Pan Tumor Zone*
- 9:45-10:05 AM** Industry Spotlight Session
Sponsored by Elucent • *HUB Theater*
- 10:15 – 10:45 AM** PSM Poster Presentations 1 • *Rare/Metastatic Cancers Zone*
- 10:15 – 10:45 AM** The Expanding Role of T-Cell Based Therapies in Cancer Care • *HUB Theater*
- 11 – 11:20 AM** Industry Spotlight Session
Sponsored by Replimune • *HUB Theater*
- 11 – 11:30 AM** “Help the Doctor”: How Best to Utilize APCs in Your Surgical Oncology Practice • *Pan Tumor Zone*
- 11:45 AM–12:15 PM** CRS and HIPEC for Unusual Primaries • *HUB Theater*
- 11:45 AM – 12:15 PM** ERAS Colorectal Surgery Update: Is Same Day Colectomy Ready for Primetime? • *Pan Tumor Zone*
- 11:45 AM – 12:15 PM** Strategies to Increase Enrollment of Diverse Populations in Clinical Trials • *Rare/Metastatic Cancers Zone*
- 12:30 – 12:50 PM** Industry Spotlight Session *Sponsored by Sirtex* • *HUB Theater*

- 12:30 – 1 PM** **Advances in Minimally Invasive Breast Cancer Surgery** • *Breast/Endocrine Zone*
- 12:30 – 1 PM** **HPB Poster Presentations 1** • *HUB Theater*
- 12:30 – 1 PM** **Regional Therapies for Soft Tissue Sarcomas** • *Melanoma & Sarcoma Zone*
- 1:15 – 1:45 PM** **Recent Advances in the Management of Thyroid Nodules** • *Breast/Endocrine Zone*
- 2:15 – 2:35 PM** **Industry Spotlight Session** *Sponsored by Lumicell* • *HUB Theater*
- 2:45 – 3:15 PM** **Breast Poster Presentations 2** • *Breast/Endocrine Zone*
- 2:45 – 3:15 PM** **Cancer in the Transgender Community** • *HUB Theater*
- 2:45 – 3:15 PM** **Sarcoma Poster Presentations 1** • *Melanoma & Sarcoma Zone*
- 3:30 – 4 PM** **Endocrine/Head & Neck Poster Presentations 1** • *Breast/Endocrine Zone*
- 3:30 – 4 PM** **How to Leverage Cooperative Groups as a Research Platform** • *HUB Theater*
- 3:30 – 4 PM** **Should HPB Cancer Surgery be Regionalized?** • *Pan Tumor Zone*
- 3:30 – 4 PM** **Melanoma Poster Presentation 1** • *Melanoma/Sarcoma Zone*
- 3:30 – 4:15 PM** **Quality Poster Presentations** • *Rare/Metastatic Cancers Zone*
- 4:45 – 5:15 PM** **Assessment and Management of Older Adults for HPB Cancer Surgery** • *HUB Theater*
- 4:45 – 5:15 PM** **Skin Cancers in Pigmented Skin** • *Melanoma Zone*
- 4:45 – 5:15 PM** **The Evolution of Novel Combination Immunotherapies – Intralesional Treatments and New Targets for Treatment** • *Immuno-Oncology Zone*

4:45 – 5:15 PM **The Role of Perioperative Immunotherapy in the Management of Resectable GEJ Adenocarcinoma** • *Pan Tumor Zone*

SSO HUB | FRIDAY, MARCH 24

- 9:45 – 10:15 AM** **Challenging Cases in Parathyroid Disease** • *Breast/Endocrine Zone*
- 9:45 – 10:15 AM** **Practical and Pragmatic Prehab** • *Rare/Metastatic Cancers Zone*
- 9:45 – 10:15 AM** **Shark Tank: What's the Next Big Clinical Trial in Pancreas Cancer** • *Pan Tumor Zone*
- 9:45 – 10:15 AM** **Strategies for Management of Lymphedema** • *Breast/Endocrine Zone*
- 10:30 – 11 AM** **Colorectal Posters Presentations 2** • *Pan Tumor Zone*
- 10:30 – 11 AM** **Surgeons Role in Driving Window of Opportunity and Neoadjuvant Immunotherapy Trials** • *Immuno-Oncology Zone*
- 11:30 – 11:50 AM** **Industry Spotlight Session** *Sponsored by Perimeter* • *HUB Theater*
- 11:30 AM – 12 PM** **Endocrine/Head & Neck Poster Presentations 2** • *Breast/Endocrine Zone*
- 11:30 AM – 12 PM** **Strategies to Reduce Surgical Site Infections** • *Immuno-Oncology Zone*
- 11:30 AM – 12 PM** **Treatment of Low Anterior Resection Syndrome** • *Pan Tumor Zone*
- 11:45 AM – 12:15 PM** **The Current Management of Desmoids: So Much More Than Surgery** • *Rare/Metastatic Cancers Zone*
- 12 – 12:30 PM** **Melanoma in Pregnancy** • *HUB Theater*
- 12:30 – 1 PM** **Norel Intraperitoneal Therapies** • *Rare/Metastatic Cancers Zone*

- 12:30 – 1 PM** **Breast Poster Presentations 3 •**
Breast/Endocrine Zone
- 12:30 – 1 PM** **Sarcoma Poster Presentations 2 •** *Melanoma/Sarcoma Zone*
- 12:30 – 1 PM** **Upper GI Poster Presentations 2 •**
Pan Tumor Zone
- 12:45 – 1:05 PM** **Industry Spotlight Session**
Sponsored by Natera • HUB Theater
- 1:15 – 1:45 PM** **HPB Poster Presentations 2 •** *Pan Tumor Zone*
- 1:15 – 1:45 PM** **Surveillance and Treatment of Anal Dysplasia •** *HUB Theater*
- 3:15 – 3:45 PM** **Melanoma Poster Presentations 2 •** *Melanoma/Sarcoma Zone*
- 3:15 – 3:45 PM** **Surgical Cytoreduction for Metastatic GIST: Who, When and Why? •** *HUB Theater*
- 4 – 4:30 PM** **Which Practice Setting is Best for Me? Exploring All the Options •** *HUB Theater*
- 4:15 – 4:45 PM** **Post-discharge VTE Prophylaxis after HPB Surgery Pro vs. Con •**
Rare/Metastatic Zone
- 5 – 5:30 PM** **Beyond HIPEC: Management of Limited Peritoneal Disease in Gastric Cancer •** *HUB Theater*
- 5 – 5:30 PM** **HPB Poster Presentations 3 •**
Pan Tumor Zone
- 6 – 6:30 PM** **Considerations for LGBTQ Breast Patients •** *Breast/Endocrine Zone*
- 6 – 6:30 PM** **Optimal Method of Reconstruction After Gastrectomy •** *Pan Tumor Zone*
- 6 – 6:30 PM** **Cutaneous Oncology Tumor Board •** *Melanoma/Sarcoma Zone*
- 6 – 6:30 PM** **PSM Poster Presentations 2 •**
Rare/Metastatic Cancers Zone

SSO HUB ZONE SPONSORS



AstraZeneca | Breast Zone

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.



Bristol Myers Squibb | Pan Tumor Zone

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients' lives through science.



Merck | Immuno-Oncology Zone

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.



Novartis | Melanoma/Sarcoma Zone

Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.




SpringWorks Therapeutics | Rare/Metastatic Cancer Zone

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers. For more information about SpringWorks Therapeutics, please visit www.springworkstx.com.



SSO HUB ENGAGER SPONSORS



Elucent Medical

Elucent Medical has created the EnVisio™ Navigation System, a device that uses innovative SmartClip™ Technology and trade secreted EnVisio Surgical Navigation for precision guidance during surgery. The integration of the navigation with your standard surgical tools provides real-time visual and audible navigation showing Distance, Depth and Direction from the tip of the cautery tool to the target + margin. Elucent Medical is founded on collaboration between physicians and is committed to improving patient outcomes.



Lumicell

Lumicell is focused on improving surgical outcomes by utilizing its innovative fluorescence-guided surgical system to remove residual cancer. The investigational Lumicell Direct Visualization System is designed to detect residual cancerous tissue within the breast cavity during the initial lumpectomy procedure. Lumicell's proprietary optical imaging agent, LUMISIGHT, is also being explored across a wide variety of solid tumor indications. For more information, please visit www.illuminatecancerrealtime.com.



Natera

Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The Signatera test is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor. Signatera is intended to detect and quantify cancer left in the body, at levels down to a single tumor molecule in a tube of blood, to identify recurrence earlier and to help optimize treatment decisions.



Perimeter Medical

Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools that address unmet medical needs. Perimeter aims to harness the power of big data, artificial intelligence, and machine learning technology to further its mission of improving the standard of care, providing better long-term outcomes for patients, and reducing healthcare costs. For more information, visit www.perimetermed.com.



Replimune

Replimune's tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune's approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity.



While oncolytic immunotherapies have shown clinical activity against tumors when given as single agents, we expect these therapies to combine with and enhance the effectiveness of several different modalities and treatments—including immunotherapy, chemotherapy, small molecules and radiation—because of the synergistic MOA and well-established safety profile.

Sirtex Medical



Sirtex Medical is a global healthcare business with offices in the U.S., Australia, Germany and Singapore, working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres.

SSO HUB SUPPORTERS



AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, vascular interventions and therapies, and oncology. Diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories drainage products, thrombolytic products and venous products. Learn more at angiodynamics.com.

Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information enabling more accurate treatment plan decisions. From its formation in 2008, Castle Biosciences has applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed (castletestinfo.com).

Clarix Imaging brings unprecedented clarity to intraoperative breast cancer lumpectomy margin visualization with our true 3D (CT) VSI-360™ Volumetric Specimen Imaging System. This advanced imaging technology takes breast surgeons and radiologists on a Journey Through the Specimen™ with views of any tissue slice from multiple angles—with no obscuring of the margins. Clarix Imaging is the only company to commercially offer a CT breast specimen imaging system.

Hologic is a global medical technology company specializing in women's health and well-being. We offer innovative solutions for screening, detecting, and treating conditions and diseases that affect women throughout their lives, including breast, gynecological and skeletal issues; cervical cancer testing; and sexually transmitted diseases. As a science-driven company, our products are backed by clinical evidence, ensuring that they perform as intended, so healthcare professionals can have greater certainty in their decisions and patients, greater peace of mind.

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to fighting cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.

At **Kubtec®**, our passion is developing transformative specimen imaging, breast cancer margin management, and specimen radiography systems that enable medical professionals to provide the best quality of care for their patients. Our proprietary award-winning technologies, such as 3D breast specimen tomosynthesis; advanced, high-resolution specimen X-ray imaging; and intelligent workflow management features, are redefining specimen radiography and breast cancer surgery standards for the 21st century.

Merit Oncology is on a mission to reduce the burden cancer places on patients and their loved ones. As a provider of world class solutions for the diagnosis, localization, and treatment of cancer, Merit Oncology consistently invests in improving our technologies and innovating new platforms to meet our physicians' needs. The preferred localization solution to treat more patients, the SCOUT® Radar Localization system has been clinically proven in over 385,000 breast and soft tissue localizations and is referenced in over 75 clinical publications.

MOLLI Surgical started in the operating room, where surgeons were using dated tools to treat cancer patients—and we knew we could do better. Our surgical wand is precise, reliable, easy to use, and built with the realities of the operating room in mind. Our technology replaces procedures to mark lesions with one that is more precise, efficient, and cost-effective. MOLLI Surgical is proud to build the advanced equipment that patients prefer to have and that physicians prefer to use.

OBP is the leading global developer of single-use, self-contained, illuminating surgical devices. We integrate light with device—making them one—creating effective and simplified single-use solutions. Our innovative products are used in surgery centers and hospitals throughout the U.S., as well as healthcare facilities worldwide.


Pacira Biosciences, Inc., is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Hynes Convention Center Map

2ND FLOOR



3RD FLOOR



The Professional Home for Cancer Surgeons Worldwide



Become a member during SSO 2023 and save \$150. Stop by the SSO Membership booth in the SSO HUB.

Join the dynamic global community of cancer surgeons to gain immediate access to educational resources via ExpertEd@SSO. Over 100 programs are available on-demand including virtual tumor boards, SurgOnc Today® podcast episodes and panel discussions. As an SSO member, you have exclusive access to special features on SSO Mobile, including *SurgOnc Question of the Week* and *Annals of Surgical Oncology* articles.

Join SSO Today!



SSO Strategic Plan

2023-2027



SSO VISION: OPTIMAL SURGICAL CANCER CARE FOR ALL

For additional information about the new strategic plan, scan the QR code.



INCREASE THE SSO'S IMPACT WORLDWIDE

- Champion Diversity, Equity, and Inclusion (DEI)
- Advocate for surgical oncology
- Develop meaningful domestic and international partnerships



ENHANCE MEMBER EXPERIENCE

- Make SSO more diverse and inclusive
- Establish SSO as the professional home for the cancer surgery team
- Strengthen member engagement and retention



ADVANCE EQUITABLE, PATIENT-CENTERED CARE

- Promote health equity in cancer care
- Provide high-quality continuing education worldwide
- Define standards of cancer care



DRIVE THE FUTURE OF CANCER CARE

- Diversify surgical oncology workforce
- Support professional growth and leadership
- Foster scientific investigation, discovery, and innovation

COMING SOON:



- ✔ SSO's New Open-Access Publication
- ✔ Companion Journal to the *Annals of Surgical Oncology*
- ✔ Manuscripts Being Accepted for Review in Summer of '23
- ✔ Published by Elsevier

Watch your inbox and social media for upcoming announcements!



SSO
SOCIETY OF
SURGICAL
ONCOLOGY

LEADING. TOGETHER.